AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Listing Regulations, please find enclosed copies of financial results of the Company for the quarter and nine months ended 31st December 2022 published in the following newspapers on 2nd February 2023: 1. Mumbai edition of Economic Times and 2. Mumbai edition of Maharashtra Times. AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 1st February 2023 at 4.00 p.m. has been uploaded on the Company's website and can be accessed through the link https://ajantapharma.com//images/EarningsCallAudioQ3(Oct-Dec)2022-23.mp3
Ajanta Pharma Results Earnings Call for Q3FY23
Conference Call with Ajanta Pharma Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript. AJANTA PHARMA LTD. - 532331 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Information on loss of share certificate AJANTA PHARMA LTD. - 532331 - Results For The Quarter And Nine Months Ended 31St December 2022
Results for the quarter and nine months ended 31st December 2022 Q3FY23 Quarterly Result Announced for Ajanta Pharma Ltd.
Ajanta Pharma announced Q3FY23 results Q3FY23: Revenue from operations at Rs 972 crore against Rs 838 crore; up 16%. EBITDA at Rs 170 crore against Rs 240 crore; EBITDA at 17% of revenue from operations. Adjusted EBITDA stands at Rs 207 crore against Rs 240 crore; Adjusted EBITDA at 21% of revenue from operations. This is after adjusting forex derivative loss of Rs 37 crore included in other expenses with forex gain in other income. Profit after tax at Rs 135 crore against Rs 192 crore; PAT at 14% of revenue from operations. 9MFY23: Revenue from operations at Rs 2,861 crore against Rs 2,471 crore, up 16%. EBITDA at Rs 588 crore against Rs 723 crore; EBITDA at 21% of revenue from operations. Adjusted EBITDA stands at Rs 631 crore against Rs 723 crore; Adjusted EBITDA at 22% of revenue from operations. This is after adjusting forex derivative loss of Rs 43 crore included in other expenses with forex gain in other income. Profit after tax at Rs 466 crore against Rs 561 crore, PAT at 16% of revenue from operations. Result PDF AJANTA PHARMA LTD. - 532331 - Board Meeting Outcome for Outcome Of Board Meeting
At the Board meeting held today, the Board has inter-alia approved and taken on record Unaudited Financial results for the quarter and nine months ended 31st December 2022. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that based on the recommendations of Nomination & Remuneration Committee meeting held today, Board has also approved the re-appointment of Mr. Yogesh Agrawal as Managing Director and Mr. Rajesh Agrawal as Joint Managing Director for a further period of five years from 1st April 2023 upto 31st March 2028, subject to approval of members. AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
`The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 25, 2023 for Aayush Agrawal, trustee Aayush Agrawal Trust AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the schedule of Earnings Conference Call to be held on 1st February 2023, post Board meeting. AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 24, 2023 for Ravi P Agrawal, Trustee Ravi Agrawal Trust